Munkvad S, Jespersen J, Gram J, Kluft C
Department of Clinical Chemistry, Ribe County Hospital, Esbjerg, Denmark.
J Am Coll Cardiol. 1991 Aug;18(2):454-8. doi: 10.1016/0735-1097(91)90600-e.
Twenty patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA) had endogenous factor XII-dependent fibrinolytic activity levels measured throughout the hospital period and those levels were prospectively correlated with the incidence of recurrent myocardial infarction until 8 weeks after hospital discharge. Within the follow-up period, recurrent myocardial infarction was observed in 8 patients, whereas the remaining 12 patients showed no clinical evidence of recurrence. The patients in the reinfarction group were characterized by a more pronounced depletion of and sustained lower levels of factor XII-dependent fibrinolytic activity than were the patients with no reinfarction (p less than 0.05). The decrease in fibrinolytic activity during rt-PA therapy was significantly associated with a depletion of functional alpha 2-antiplasmin, the primary plasmin inhibitor. These results indicate that, paradoxically, coronary thrombolysis with rt-PA involves depletion of endogenous factor XII-dependent fibrinolytic activity levels, which constitutes a risk for early myocardial reinfarction.
20例接受重组组织型纤溶酶原激活剂(rt-PA)治疗的急性心肌梗死患者在整个住院期间均测定了内源性因子Ⅻ依赖性纤溶活性水平,并对这些水平与出院后8周内复发性心肌梗死的发生率进行了前瞻性关联研究。在随访期内,8例患者发生了复发性心肌梗死,而其余12例患者未出现复发的临床证据。再梗死组患者的特点是,与未再梗死的患者相比,因子Ⅻ依赖性纤溶活性的消耗更明显且持续处于较低水平(p<0.05)。rt-PA治疗期间纤溶活性的降低与功能性α2-抗纤溶酶(主要的纤溶酶抑制剂)的消耗显著相关。这些结果表明,矛盾的是,rt-PA进行冠状动脉溶栓涉及内源性因子Ⅻ依赖性纤溶活性水平的消耗,这构成了早期心肌再梗死的风险。